AGTR1 and cardiovascular disorder: Altogether, it seems that in cardiovascular diseases treatment, the ideal ligand for AT1R would be that one acting as an antagonist of the canonical G-protein pathway but at the same time as agonist of the receptor conformation promoting the non-canonical pathway through β-arrestin signaling.